Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
The positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so respondents to Scrip’s question “which therapeutic area will see the greatest advances in 2023?”
The biopharma industry’s high investment in different approaches to cancer is also driving expectations around continuing overall progress in oncology,...
Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.
Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.
As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
